erlotinib hydrochloride has been researched along with prednisolone in 4 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (prednisolone) | Trials (prednisolone) | Recent Studies (post-2010) (prednisolone) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 34,414 | 3,302 | 7,141 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | prednisolone (IC50) |
|---|---|---|---|
| Glucocorticoid receptor | Homo sapiens (human) | 0.0278 | |
| Progesterone receptor | Homo sapiens (human) | 2.08 | |
| Glucocorticoid receptor | Rattus norvegicus (Norway rat) | 0.0565 | |
| Glycine receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | 0.016 | |
| Mineralocorticoid receptor | Homo sapiens (human) | 0.0322 | |
| Glycine receptor subunit beta | Rattus norvegicus (Norway rat) | 0.016 | |
| Glycine receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | 0.016 | |
| Glycine receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | 0.016 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boeck, S; Hausmann, A; Heinemann, V; Reibke, R; Schulz, C | 1 |
| Ishida, T; Katsuura, Y; Minemura, H; Misa, K; Munakata, M; Tachihara, M; Uematsu, M | 1 |
| Fujii, S; Kashiwabara, K; Semba, H; Tsumura, S | 1 |
| Cho, SL; Chuang, CA; Lai, CF; Liao, WY; Lin, WC | 1 |
4 other study(ies) available for erlotinib hydrochloride and prednisolone
| Article | Year |
|---|---|
Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Exanthema; Gemcitabine; Glucocorticoids; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prednisolone; Quinazolines; Radiography | 2007 |
Increase of ascites and pleural effusion misleading assessment of antitumor response to erlotinib in adenocarcinoma of the lung.
Topics: Adenocarcinoma; Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Ascites; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Pleural Effusion, Malignant; Prednisolone; Quinazolines | 2011 |
Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Mutation; Prednisolone; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Tubulointerstitial nephritis associated with erlotinib therapy for lung cancer.
Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Biopsy; Erlotinib Hydrochloride; Glucocorticoids; Humans; Kidney; Kidney Function Tests; Lung Neoplasms; Male; Nephritis, Interstitial; Prednisolone; Recovery of Function; Withholding Treatment | 2020 |